{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T23:39:33Z","timestamp":1792366773760,"version":"4.4.0"},"reference-count":44,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Histopathology"],"abstract":"<jats:p>Neoadjuvant therapy has been recently established as the standard of care in surgically resectable stage III melanoma. Insofar as the extent of tumour response correlates with metrics of patient survival, this underscores the critical ongoing need for rigorous and reproducible approaches to pathological response assessment following surgery. In the current review, we provide a historical overview of early trials assessing safety and efficacy of neoadjuvant targeted and immune therapy, and we summarize the earliest and revised recommendations for pathological response assessment of treated melanoma specimens. Moreover, we highlight that not only the extent of response but also the composition of that response correlates with recurrence\u2010free survival in these high\u2010risk patients.<\/jats:p>","DOI":"10.1111\/his.70281","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:50:56Z","timestamp":1792363856000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathological assessment of neoadjuvant\u2010treated melanoma specimens: a historical overview, lessons learned along the way and the road ahead"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0655-4963","authenticated-orcid":false,"given":"Robert","family":"Rawson","sequence":"first","affiliation":[{"name":"Melanoma Institute Australia The University of Sydney  Sydney New South Wales Australia"},{"name":"Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"},{"name":"Department of Tissue Pathology and Diagnostic Oncology Royal Prince Alfred Hospital and NSW Health Pathology  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-4922","authenticated-orcid":false,"given":"Elizabeth M.","family":"Burton","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine UT MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7899-4138","authenticated-orcid":false,"given":"Michael T.","family":"Tetzlaff","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Dermatology, Dermatopathology and Oral Pathology Unit University of California San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"key":"e_1_2_16_2_1","first-page":"472","article-title":"Melanoma staging: Evidence\u2010based changes in the American joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald JE","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"e_1_2_16_3_1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2105\/AJPH.2020.305567","article-title":"New systematic therapies and trends in cutaneous melanoma deaths among US whites, 1986\u20132016","volume":"110","author":"Berk\u2010Krauss J","year":"2020","journal-title":"Am. J. Public Health"},{"key":"e_1_2_16_4_1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five\u2010year survival with combined Nivolumab and Ipilimumab in advanced melanoma","volume":"381","author":"Larkin J","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_16_5_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000391","article-title":"Overall survival at 5\u2009years of follow\u2010up in a phase III trial comparing ipilimumab 10\u2009mg\/kg with 3\u2009mg\/kg in patients with advanced melanoma","volume":"8","author":"Ascierto PA","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"e_1_2_16_6_1","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow\u2010up confirms recurrence\u2010free survival benefit of adjuvant Pembrolizumab in high\u2010risk stage III melanoma: Updated results from the EORTC 1325\u2010MG\/KEYNOTE\u2010054 trial","volume":"38","author":"Eggermont AMM","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_16_7_1","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu J","year":"2016","journal-title":"Cancer Discov."},{"key":"e_1_2_16_8_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high\u2010risk, surgically resectable melanoma: A single\u2010centre, open\u2010label, randomised, phase 2 trial","volume":"19","author":"Amaria RN","year":"2018","journal-title":"Lancet Oncol."},{"key":"e_1_2_16_9_1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB\u2010C, BRAFV600 mutation\u2010positive melanoma (NeoCombi): A single\u2010arm, open\u2010label, single\u2010centre, phase 2 trial","volume":"20","author":"Long GV","year":"2019","journal-title":"Lancet Oncol."},{"key":"e_1_2_16_10_1","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high\u2010risk resectable melanoma","volume":"24","author":"Amaria RN","year":"2018","journal-title":"Nat. Med."},{"key":"e_1_2_16_11_1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank CU","year":"2018","journal-title":"Nat. Med."},{"key":"e_1_2_16_12_1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD\u20101 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang AC","year":"2019","journal-title":"Nat. Med."},{"key":"e_1_2_16_13_1","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN\u2010neo): A multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman EA","year":"2019","journal-title":"Lancet Oncol."},{"key":"e_1_2_16_14_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41591-020-0829-0","article-title":"Learning from clinical trials of neoadjuvant checkpoint blockade","volume":"26","author":"Versluis JM","year":"2020","journal-title":"Nat. Med."},{"key":"e_1_2_16_15_1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2010adjuvant or adjuvant\u2010only Pembrolizumab in advanced melanoma","volume":"388","author":"Patel SP","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_16_16_1","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable stage III melanoma","volume":"391","author":"Blank CU","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_16_17_1","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41591-023-02336-1","article-title":"Neoadjuvant immunotherapy for melanoma is now ready for clinical practice","volume":"29","author":"Garbe C","year":"2023","journal-title":"Nat. Med."},{"key":"e_1_2_16_18_1","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.22.02575","article-title":"Neoadjuvant checkpoint immunotherapy and melanoma: The time is now","volume":"41","author":"Long GV","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_16_19_1","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"Neoadjuvant systemic therapy in melanoma: Recommendations of the international neoadjuvant melanoma consortium","volume":"20","author":"Amaria RN","year":"2019","journal-title":"Lancet Oncol."},{"key":"e_1_2_16_20_1","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1245\/s10434-021-11236-y","article-title":"Neoadjuvant systemic therapy (NAST) in patients with melanoma: Surgical considerations by the international neoadjuvant melanoma consortium (INMC)","volume":"29","author":"Akkooi ACJ","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"e_1_2_16_21_1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff MT","year":"2018","journal-title":"Ann. Oncol."},{"key":"e_1_2_16_22_1","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","article-title":"Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: Recommendations from an international working group","volume":"28","author":"Provenzano E","year":"2015","journal-title":"Mod. Pathol."},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.1237"},{"key":"e_1_2_16_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.018"},{"key":"e_1_2_16_25_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the international neoadjuvant melanoma consortium (INMC)","volume":"27","author":"Menzies AM","year":"2021","journal-title":"Nat. Med."},{"key":"e_1_2_16_26_1","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.annonc.2020.07.016","article-title":"Histopathological features of complete pathological response predict recurrence\u2010free survival following neoadjuvant targeted therapy for metastatic melanoma","volume":"31","author":"Tetzlaff MT","year":"2020","journal-title":"Ann. Oncol."},{"key":"e_1_2_16_27_1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.annonc.2021.03.006","article-title":"Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma","volume":"32","author":"Rawson RV","year":"2021","journal-title":"Ann. Oncol."},{"key":"e_1_2_16_28_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100776","article-title":"Longitudinal analysis reveals dynamic changes in histopathologic features in responders to neoadjuvant treatment in a stage III BRAF\u2010mutant melanoma cohort","volume":"38","author":"Braden J","year":"2025","journal-title":"Mod. Pathol."},{"key":"e_1_2_16_29_1","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1158\/1078-0432.CCR-23-3775","article-title":"Tumor\u2010infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti\u2010PD\u20101 therapy correlate with pathologic response and recurrence\u2010free survival","volume":"30","author":"Ma KL","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_16_30_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-025-02435-0","article-title":"CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non\u2010small\u2010cell lung cancer patients","volume":"10","author":"Lin H","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"e_1_2_16_31_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamasurg.2021.7554","article-title":"Representativeness of the index lymph node for Total Nodal Basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma","volume":"157","author":"Reijers ILM","year":"2022","journal-title":"JAMA Surg."},{"key":"e_1_2_16_32_1","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response\u2010directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high\u2010risk stage III melanoma: The PRADO trial","volume":"28","author":"Reijers ILM","year":"2022","journal-title":"Nat. Med."},{"key":"e_1_2_16_33_1","doi-asserted-by":"crossref","first-page":"S1600","DOI":"10.1016\/j.annonc.2025.09.069","article-title":"LBA57 two\u2010year clinical update and first biomarker analyses of the phase III NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma","volume":"36","author":"Lucas MW","year":"2025","journal-title":"Ann. Oncol."},{"key":"e_1_2_16_34_1","doi-asserted-by":"crossref","first-page":"S1288","DOI":"10.1016\/j.annonc.2023.10.042","article-title":"LBA48 pathologic response and exploratory analyses of neoadjuvant\u2010adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb\u2010IV melanoma from SWOG S1801","volume":"34","author":"Patel S","year":"2023","journal-title":"Ann. Oncol."},{"key":"e_1_2_16_35_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100353","article-title":"Pathologic processing of lung cancer resection specimens after neoadjuvant therapy","volume":"37","author":"Weissferdt A","year":"2024","journal-title":"Mod. Pathol."},{"key":"e_1_2_16_36_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.107699","article-title":"Concordance of pathologic response assessment between local and central review in melanoma: A post hoc analysis of KEYMAKER\u2010U02 substudy 02C","volume":"11","author":"Tetzlaff M","year":"2026","journal-title":"ESMO Open"},{"key":"e_1_2_16_37_1","first-page":"272","article-title":"Neoadjuvant PD\u20101 blockade in surgically resectable desmoplastic melanoma: Cohort a of the phase 2 SWOG S1512 trial","volume":"7","author":"Kendra KL","year":"2026","journal-title":"Nat. Can."},{"issue":"17","key":"e_1_2_16_38_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9501","article-title":"Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and\/or nodal metastases","volume":"42","author":"Hauschild A","year":"2024","journal-title":"JCO"},{"key":"e_1_2_16_39_1","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.ccell.2024.10.007","article-title":"Neoadjuvant vidutolimod and nivolumab in high\u2010risk resectable melanoma: A prospective phase II trial","volume":"42","author":"Davar D","year":"2024","journal-title":"Cancer Cell"},{"key":"e_1_2_16_40_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2021.02.012","article-title":"Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma","volume":"148","author":"Versluis JM","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010025\u201018191\u2010y"},{"key":"e_1_2_16_42_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011483","article-title":"FDG\u2010PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma","volume":"13","author":"Zhou L","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"e_1_2_16_43_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s13046-024-03153-1","article-title":"Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy","volume":"43","author":"Chan WY","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"e_1_2_16_44_1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN\u2010neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman EA","year":"2021","journal-title":"Nat. Med."},{"key":"e_1_2_16_45_1","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221952","article-title":"IFN\u2010\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma","volume":"220","author":"Reijers ILM","year":"2023","journal-title":"J. Exp. Med."}],"container-title":["Histopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.70281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/his.70281","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.70281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:51:01Z","timestamp":1792363861000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/his.70281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":44,"alternative-id":["10.1111\/his.70281"],"URL":"https:\/\/doi.org\/10.1111\/his.70281","archive":["Portico"],"relation":{},"ISSN":["0309-0167","1365-2559"],"issn-type":[{"value":"0309-0167","type":"print"},{"value":"1365-2559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,18]]},"assertion":[{"value":"2026-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"his.70281"}}